中文 |
English |
Email Alert
增生平用于口腔癌化学预防
Chemoprevention of Oral Cancer by a Mixture of Chinese Herbs (Anti-Tumor Mixture B)
增生平(ZSP,又称anti-tumor B,ATB)是一种由山豆根、拳参、北败酱、夏枯草、白鲜皮、黄药子等组成的中药复方。以前的研究显示增生平对人食管癌(主要是鳞状细胞癌)有显著的化学预防效用。我们系统地研究评价了增生平对4-硝基喹啉-1-氧化物诱导的A/J 小鼠口腔癌发生发展的影响,发现增生平减少了约60% 的口腔癌。对7,12-二甲苯并(a)蒽诱导的仓鼠口腔癌也观察到了类似的结果。进而在口腔白斑患者中开展了一个随机临床实验,结果发现增生平(每日三次,每次4 片,持续8—12 个月)在68% 的患者中减少了口腔病变的大小,而在安慰剂组只有17%(P<0.01)。这些结果显示增生平可能是一种强效的人口腔癌化学预防试剂。
Anti-tumor B (ATB) is a Chinese herbal mixture of six plants (Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus and Dioscorea bulbifera). ATB is also called Zeng Sheng Ping (ZSP). Previous studies have shown significant chemopreventive efficacy of ATB against human esophageal cancer, mostly squamous cell carcinomas. The chemopreventive effects of ATB on the development of 4-nitroquinoline-1-oxide (4NQO) induced oral squamous cell carcinomas in A/J mice were systematically evaluated and it was found that ATB reduced 4NQO-induced oral cancer development by approximately 60%. Similar results were also seen in 7,12-dimethylbenz(a)anthracene (DMBA) induced oral cancer in hamsters. A randomized clinical trial was conducted in patients with oral leukoplakia. Treatment with ATB (4 tablets, 3 times per day for 8—12 months) reduced the size of oral lesions in 68% of the patients versus 17% of the patients in the placebo control group (P < 0.01). These results indicate that ATB may be a potent chemopreventive agent against the development of oral cancer in humans.
增生平
antitumor B
[1] Sun Z, Guan X, Li N, Liu X, Chen X. Oral Oncol., 2010, 46: 105—110
[2] Lin P Z, Zhang J S, Cao S G, Rong Z P, Gao R Q, Han R, Shu S P. Chinese Journal of Oncology, 1988, 10: 161—166
[3] Lin P, Zhang J, Rong Z, Han R, Xu S, Gao R, Ding Z, Wang J, Feng H, Cao S. Proc. Chin. Acad. Med. Sci. Peking Union Med. Coll., 1990, 5: 121—129
[4] Lin P. Acta Academiae Medicinae Sinicae, 1990, 12: 235—245
[5] Fan X. Acta Academiae Medicinae Sinicae, 1993, 15: 71—73
[6] Zhang Z, Wang Y, Yao R, Li J, Yan Y, La Regina M, Lemon W L, Grubbs C J, Lubet R A, You M. Oncogene, 2004, 23: 3841—3850
[7] Wang Y, Zhang Z, Garbow J R, Rowland D J, Lubet R A, Sit D, Law F, You M. Cancer Prev. Res. (Phila), 2009, 2: 634—640
[8] Andre K, Schraub S, Mercier M, Bontemps P. Eur. J. Cancer B Oral Oncol., 1995, 31B: 301—309
[9] Iribarren C, Tekawa I S, Sidney S, Friedman G D. N. Engl. J. Med., 1999, 340: 1773—1780
[10] Murata M, Takayama K, Choi B C, Pak A W. Cancer Detect. Prev., 1996, 20: 557—565
[11] Spitz M R. Semin. Oncol., 1994, 21: 281–288
[12] Winn D M. Adv. Exp. Med. Biol., 1992, 320: 39—46
[13] Jemal A, Siegel R, Xu J, Ward E. CA Cancer J. Clin., 2010, 60(5): 277—300
[14] 周曾同(Zhou Z T). 中华口腔医学杂志(Chinese Journal of Stomatology), 2006, 41(8): 502—505
[15] Forastiere A, Koch W, Trotti A, Sidransky D. N. Engl. J. Med., 2001, 345(26): 1890—1900
[16] Steidler N E, Reade P C. Oral Surg. Oral. Med. Oral Pathol., 1984, 57: 524—531
[17] Yuan B, Heniford B W, Ackermann D M, Hawkins B L, Hendler F J. Cancer Res., 1996, 54: 5310—5317
[18] Zhang Z, Wang Y, Yao R, Lubet R A, You M. Mol. Cancer Res., 2006, 4: 401—410
[19] Wang Y, Yao R, Gao S, Wen W, Du Y, Szabo E, Hu M, Lubet R A, You M. Mol. Carcinog., 2013, 52(1): 49—56
[20] Gao G. Comparative pharmacokinetics of matrine: pure matrine vs crude chemical in ACAPHA. Doctoral Dissertation, Simon Fraser University, Burnaby, British Columbia, Canada, 2007
[21] Gao G, Law F C. Drug Metab. Dispos., 2009, 37: 884—891
[22] Christensen M E, Therkildsen M H, Hansen B L, Albeck H, Hensen G N, Bretlau P. Eur. Arch. Otorhinolaryngol., 1992, 249: 243—247
[23] Hiraishi Y, Wada T, Nakatani K, Negoro K, Fujita S. Pathol. Oncol. Res., 2006, 12: 87—91
[24] Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, Fong D, Barbieri V, Jank S, Doppler W, Rasse M, Norer B. Oral Oncol., 2007, 43: 193—198
[25] Sarkis S A, Abdullah B H, Abdul M B A, Talabani N G. Head Neck Oncol., 2010, 2: 13
[26] Guan X B, Sun Z, Chen X X, Wu H R, Zhang X Y. Chin. Med. J. (Engl), 2012, 125: 332—337
[27] Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L, Clerici M, Formelli F, Barzan L, Carrassi A, et al. Eur. J. Cancer B, Oral Oncol., 1992, 28B: 97—102
[28] Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, Mariani L, Formelli F, Giardini R, Costa A, De Palo G, et al. J. Cell. Biochem. Suppl., 1993, 17F: 255—261
[29] Benner S E, Winn R J, Lippman S M, Poland J, Hansen K S, Luna M A, Hong W K. J. Natl. Cancer Inst., 1993, 85: 44—47
[30] Garewal H. Eur. J. Cancer Prev., 1994, 3: 101—107
[31] Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran P R, Menon V, Jayadeep A, Nair M K, Mathews C, Mahalingam T R, Balaram P, Nair P P. Oral Oncol., 1997, 33: 231—236
[32] Armstrong W B, Kennedy A R, Wan X S, Taylor T H, Nguyen Q A, Jensen J, Thompson W, Lagerberg W, Meyskens F L Jr. Clin. Cancer Res., 2000, 6: 4684—4691
[33] Halder A, Raychowdhury R, Ghosh A, De M. J. Environ. Pathol. Toxicol. Oncol., 2005, 24: 141—144
[34] Shumway B S, Kresty L A, Larsen P E, Zwick J C, Lu B, Fields H W, Mumper R J, Stoner G D, Mallery S R. Clin. Cancer Res., 2008, 14: 2421—2430
[35] Awad A B, Fink C S. J. Nutr., 2000, 130: 2127—2130
[36] Raicht R F, Cohen B I, Fazzini E, Sarwal A, Takahashi M. J. Cancer Res., 1980, 40: 403—405
[37] Awad A B, Gan Y, Fink C S. Nutr. Cancer, 2000, 36: 74—78
[38] Awad A B, Down A C, Fink C S. Int. J. Mol. Med., 2000, 5: 541—546
[39] Rao A V, Janezic S A. Nutr. Cancer, 1992, 18: 43—52
[40] von Holtz R L, Fink C S, Awad A B. Nutr. Cancer, 1998, 32: 8—12
[41] Awad A B, Downie A C, Fink C S, Kim U. Anticancer Res., 2000, 20: 821—824
[42] Awad A B, Williams H, Fink C S. Nutr. Cancer, 2001, 40: 157—164
/
| 〈 |
|
〉 |
PDF
(924KB)
